Archive | November, 2019

Life Science Nation’s, Focus on Cures Accelerator (FOC), Now Offering a Fundraising Campaign Curriculum

27 Nov

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

LSN recently launched the Focus on Cures (FOC) Accelerator that helps high-growth, international startup companies move into the global partnering arena through a two-week Boston-based immersion program, titled MKT 466: Funding and Partnering Immersion Course, integrated into LSN’s global partnering network and the RESI conference series. The theme of the FOC accelerator is to create a funnel of elite, top domestic and foreign startups that need to raise angel, seed, series A and B rounds. This course solves an early stage funding challenge: there is no standardized methodology for teaching a company how to brand and message itself and efficiently manage a fundraising campaign. There is no reliable, accurate, and current partner and investor database (besides LSN’s) to get a company a list of global partners that are a fit for their stage of development and product set. Very few entrepreneurs are actually taught how to launch and manage a fundraising campaign, never mind training CEOs how to make an introductory phone call or write an introductory email. Most importantly, no one teaches the holy grail of canvassing for capital, which is, how to follow up.

– Incubator
– Accelerator
– Government Agency
– Private Firm Seeking Funding

Participants in the course receive:

  • A year subscription to the LSN investor database, valued at $6,995
  • Branding and messaging collateral for fund raising campaign, (including a logo, tagline, one page data sheet, two page executive summary, and 10-12 slide pitch), valued at $15K
  • A ticket to the next RESI conference to launch the fundraising campaign, valued at $3,000

The course is $10,000 per company, for services valued at $25,000, held at the LSN corporate headquarters in Downtown Crossing, Boston. Each company is expected to send one business and one science executive for the two week immersion class. The first class will be held from May 25th through Jun 5th, leading up to RESI San Diego, taking place on Monday, June 8th.

FOC Accelerator – MKT 466 Funding and Partnering Immersion Course

MKT466 is a unique two-week immersion course designed for life science entrepreneurs to experience the best methodologies for reaching out and establishing a dialogue with partners and  investors, building a relationship and, ultimately, securing capital allocations.

The morning sessions are 3-hour classes teaching the fundamental business development and marketing skills needed to formulate a company theme, create a corporate brand with appropriate messaging and market your firm to investors and strategic partners within the life science arena. (See details in the morning class outline)

The afternoon sessions include 1 hour of meeting the players in the Massachusetts life science ecosystem and 2 hours of curating and reaching out to a list of global investors and channel partners:

  1. Utilize LSN’s Company Database to build a full picture of global landscape of competitors
  2. Utilize LSN’s Investor Database to find investors and partners that are a fit for your stage of development and product set and aggregate a global target list
  3. Refine investor-centric marketing collateral (following the instructions of the Branding and Messaging class)
  4. Leverage your infrastructure to do email marketing campaigns and nurture leads in a CRM
  5. Start email and phone canvassing each day, supervised and mentored by LSN expert BD staff
  6. Set up intro phone calls and meetings
  7. Prepare for the upcoming RESI conference

NEW! RESI Launches Featured Company Pitch Session

27 Nov

By Karen Deyo, Senior Investor Research Analyst, LSN

Are you looking to raise a private financing round or find a strategic partner for your life science startup?  The 27th Redefining Early Stage Investments (RESI) Partnering Conference is offering an opportunity to present your firm at our San Francisco event taking place on January 14th, 2020 event taking place at the Marines’ Memorial Club and Hotel near Union Square. We expect 500+ early stage investors to attend RESI San Francisco 2020, making this a unique opportunity to get your company’s message out.

Featured Pitch Sessions

Early Stage firms seeking licensing deals or Seed, Angel, Series A or B funding can secure a 15-minute presentation slot at the upcoming RESI Partnering Conference.  With RESI’s focused audience of life science investors, and a 1:1 ratio of investors to startups, presenting at RESI is a unique opportunity to get in front of early stage partners. RESI will host over 500 global early stage investors ranging from family offices and angels to strategic Pharma and MedTech players. Presenting at RESI gives companies an opportunity to build their profile.

If your firm is interested in presenting in the Early Stage Company Pitch Sessions please click below.  You will be required to submit a two-page executive summary and 10-12 page pitch deck with your application.

Deadline for applications December 12th 2019.

Fee structure

  • RESI registration fee per attendee (register here)
  • Presentation fee per company:  $1,500 

Who should present?

Any life science company that is developing products in the Drugs, Devices, Diagnostics or Digital Health arena and is seeking licensing or investment.

Presentation Details:

  • Early Stage companies are invited to request a 15-minute company presentation.
  • Presenting companies will be featured in the LSN Newsletter, RESI website and in the RESI conference program guide.

What about the RESI Innovation Challenge?

Those who are familiar with RESI know of the RESI Innovation Challenge, a competition for companies on the day of the conference, where they present posters in the exhibit hall and compete for ‘investments’ of ‘RESI Cash’ from attendees, with the most successful winning prizes at the end of the day. The RESI Innovation Challenge is unique in that it involves a rigorous merit-based selection process that assesses the ‘investability’ of a company based on the innovativeness of their technology, the stage of development and potential market size, to name a few of the many criteria. The Innovation Challenge has always been extremely selective, with many more applying than are accepted to participate. Participation in the Innovation Challenge for selected companies is at no extra cost, to ensure that the selective nature of the Innovation Challenge remains solely merit based (apply here). However, we have found that a large number of companies would like the opportunity to present their companies to the broad audience in attendance at RESI. To accommodate them, we are launching the RESI Featured Company Pitch Sessions.

RESI BACK TO EUROPE IN 2020! Save the Date!

27 Nov

By Gregory Mannix, Vice President International Business Development, LSN

RESI is returning to the Old Continent for the 2nd RESI Europe conference, this time to be held at the Hyatt Regency Etoile in Paris on March 23rd, 2020. Mark your calendar because you will not want to miss this unique gathering of 200+ global early stage life science investors.

Hot Investor Mandate: Taiwan Cross-Border Investment Firm Seeks Breakthrough Technologies in Healthcare Including Therapeutics, Diagnostics, Digital Health

27 Nov

A venture capital firm in Taiwan invests in breakthrough technologies changing healthcare. The firm invests from seed-Series A. The fund’s LP’s include groups in the healthcare sector.

The firm invests in early stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm’s partners have a strong clinical perspective; the firm has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Subsidsiary of China Family Office Backed Corporation Seeks Cross Border Investment Opportunities in Early-Stage Therapeutics, Devices, and In Vitro Diagnostics

27 Nov

A subsidiary of a company that is sponsored by family offices in China is focused on research and distribution of class 2 and 3 medical devices in China, and is one of the major distributors for some of the largest multinational companies. Having offices in both USA and China, the firm has invested in companies that are based in greater Boston area, Los Angeles as well as Canada. The firm has a fund size of $30M, and the typical allocation ranges from $0.5M – $1M, with no specific limit. The firm has invested over 10 companies by now and will continue to expand its portfolio.

The firm is open to therapeutics and medical device companies, but is most interested in in-vitro diagnostic technologies. The firm is looking for companies that are in development or in the pre-clinical stage. The firm mostly invests in seed round but will invest up to pre-A. The firm is also interested in in-licensing opportunities in China as well.

The firm invests globally and does not have specific requirements regarding companies or their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Venture Fund Invests in Growth-Stage Healthcare IT and Pharma IT Companies

27 Nov

An early stage venture fund based in the USA generally makes equity investments in Healthcare IT and Pharma IT companies at growth stage. The typical investment size ranges from $1 million to $3 million. The firm focuses on companies based in the mid-Atlantic region of the USA.

The firm is currently looking for new opportunities in the Healthcare IT and Pharma IT sectors. The firm will not consider devices or biotech companies. The firm typically invests in companies that have started to generate revenues.

The firm focuses on private companies with between $1 million to $3 million in revenue. The firm prefers investments in companies with a strong management team and significant growth potential.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: China-Based Investment Company Invests in Early-Stage Life Science Investment Opportunities with China Angle, with Capacity to Invest Over $10M

27 Nov

An investment company with base operations in China manages a¥3000M fund. The typical allocation size of the firm ranges from ¥50M to ¥100M (~$7 to 14M USD). The firm is generally interested in companies in therapeutics, medical devices, diagnostics, and healthcare IT areas.

The firm is interested in the medical device, diagnostics, and Healthcare IT companies. Within the therapeutics sector, the firm will mainly look at CRO and CDMO companies and it prefers companies with unique R&D platforms. The firm will look at companies that are in development and it is most interested in companies that are closed to commercialize or are already on the market. The firm prefers to invest in early-stage companies that are FDA/CE/NMPA approved or are closed to getting NMPA approval. The firm is willing to help its portfolio companies to expand their commercialization in Chinese market.

The firm prefers companies from China, but will also invest in foreign companies with China angles or China market or those who have branches in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.